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Staphylococcus aureus is one of the most causative agents of mastitis and is associ-
ated with chronic udder infections. The persistency of the pathogen is believed to be 
the result of an insufficient triggering of local inflammatory signaling. In this study, the 
preclinical mastitis model was used, aiming to evaluate if lipopolysaccharide (LPS) or 
lipoteichoic acid (LTA) preconditioning could aid the host in more effectively clearing or 
at least limiting a subsequent S. aureus infection. A prototypic Gram-negative virulence 
factor, i.e., LPS and Gram-positive virulence factor, i.e., LTA were screened whether 
they were able to boost the local immune compartment. Compared to S. aureus- 
induced inflammation, both toxins had a remarkable high potency to efficiently induce 
two novel selected innate immunity biomarkers i.e., lipocalin 2 (LCN2) and chitinase 
3-like 1 (CHI3L1). When combining mammary inoculation of LPS or LTA prior to a local 
S. aureus infection, we were able to modulate the innate immune response, reduce local 
bacterial loads, and induce either LCN2 or CHI3L1 at 24 h post-infection. Clodronate 
depletion of mammary macrophages also identified that macrophages contribute only to 
a limited extend to the LPS/LTA-induced immunomodulation upon S. aureus infection. 
Based on histological neutrophil influx evaluation, concomitant local cytokine profiles and 
LCN2/CHI3L1 patterns, the macrophage-independent signaling plays a major role in the 
LPS- or LTA-pretreated S. aureus-infected mouse mammary gland. Our results highlight 
the importance of a vigilant microenvironment during the innate immune response of 
the mammary gland and offer novel insights for new approaches concerning effective 
immunomodulation against a local bacterial infection.
Keywords: intramammary injection, Staphylococcus aureus, mastitis, lipopolysaccharide, lipoteichoic acid, 
chitinase 3-like 1, lipocalin 2
inTrODUcTiOn
Antibiotic-resistant bacteria remain a serious problem in modern health care, food safety, and 
animal health, resulting in an urgent need for alternatives to replace the conventional curative 
treatment (1, 2). The ideal strategy would be that (mis)used antibiotics become obsolete or can at 
least be partly replaced by preventive treatment. The latter strategy modulates the immune system 
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by a primary insult that enhances the activity of a beneficial 
antibacterial host response which, in turn, clears the bacterial 
hazard when it presents itself (3). In contrast to previous litera-
ture, it is now more accepted that next to the adaptive immunity, 
the innate immunity can also harbor some immunological 
memory (4).
Mastitis is a disease featured by either chronically or acutely 
inflamed mammary glands and is still a major challenge in the 
dairy sector as it affects both milk quality and animal welfare 
(5, 6). Staphylococcus aureus (S. aureus) in the udder of dairy 
cows causes harmful clinical symptoms and is associated with 
poor cure rates (7). The insufficient recognition of the infecting 
S. aureus in the mammary compartment is believed to hinder 
the host in raising an adequate innate immune response and 
the pathogen may, therefore, persist in the tissue (8, 9). In addi-
tion, these Gram-positive bacteria may infiltrate the mammary 
epithelial cell (MEC) layers and induce complicating factors 
such as biofilms formation (10, 11). Altogether, these observa-
tions are recognized to be a reason why classical antibiotic 
therapies have difficulties in eradicating contagious infections 
from a herd. Moreover, this currently leads to excessive use of 
antibiotics and even drug-resistant variants of mastitis pathogens 
(12–14). Commercial efforts have been made to create S. aureus 
mastitis vaccines e.g., Lysigin (Boehringer Ingelheim Vetmedica, 
Inc.) and Startvac (Hipra, Inc.) as an alternative to antibiotics. 
Unfortunately, many of these strategies have shown limited 
efficacy under field conditions (15).
The mammary gland is an immune receptive organ that har-
bors different kinds of pathogen recognition receptors (PRRs) 
on local cells (16). It is accepted that the outcome of the inflam-
matory reaction in this niche strongly depends on the efficiency 
of activating local PRR-expressing cells through the recogni-
tion of pathogen-associated molecular patterns (PAMPs) (17). 
Gram-negative mastitis pathogens contain several highly 
potent PAMPs that trigger multiple PRRs during an intramam-
mary infection and result in a cytokine storm associated with 
acute symptoms at the cow’s udder. These events eventually 
induce either a fast recovery or a negative outcome (18, 19). 
By contrast, the comprehensive identification of Gram-positive 
pathogens by the innate immune system is impeded due to a 
smaller number of highly potent immunodominant proteins 
that typically mediate much milder symptoms and chronic 
infections (20–23). Unraveling the inflammatory mechanisms 
that are triggered by different bovine mastitis pathogens and 
boost the host’s immunity for low immunopotent bacterial 
strains such as S. aureus remain, therefore, mandatory. Such 
experiments in cows are severely limited with respect to 
availability of immunological research tools and requested 
infrastructure. Complementing in vitro bovine models, in vivo 
mouse models were developed to tackle these major drawbacks 
(24). The latter preclinical models allow the dynamic interac-
tion between mammary gland cell populations and have been 
successfully used with different mastitic bacteria, including 
bovine S. aureus isolates, focusing on the early innate immune 
response that is highly conserved between both mammalian 
species (25).
Until recently, the main focus with regard to PRR-containing 
mammary cells was on the MECs as these were expected to be 
the key cell type responsible for sensing of mastitis pathogens 
(17, 26). Nevertheless, novel data indicate that the mammary 
compartment is an immunological microenvironment where 
multiple innate immune cells are present that are also able to 
sense virulence factors of pathogens (27). The differential role of 
the sentinel cell types responsible for immunosurveillance during 
an infection is gaining increasing importance in the mammary 
gland immunity field (28–32). It is also currently, albeit partly, 
known that the mammary epithelium communicates with 
other PRR-containing cells in the mammary gland for bacterial 
recognition, e.g., by shedding PAMPs such as CD14 and likely 
also through microRNA (33, 34). However, whether appropriate 
activation of this microenvironment may trigger subsequent anti-
bacterial or anti-inflammatory responses to a secondary insult 
remains largely unknown.
The aim of this paper was to analyze the antibacterial capacity 
of the mammary microenvironment against S. aureus mastitis 
using an intraductal inoculation mouse model. First, the innate 
immune response of the mammary compartment resulting 
from exposure to virulence factors lipopolysaccharide (LPS) 
and lipoteichoic acid (LTA) or the well characterized bovine 
mastitis isolate S. aureus Newbould 305 was investigated. 
Second, we assessed immunomodulation and the antibacterial 
response of the complete mammary microenvironment by LPS 
or LTA on a subsequent insult with S. aureus. Third, we veri-
fied whether the preconditioning by either LPS or LTA to a S. 
aureus infection in our mouse model was unique for the local 
macrophages or whether other MECs are of essence for this 
beneficial response.
For the analysis of the host immune response in the differ-
ent experiments, we preferred to measure lipocalin 2 (LCN2) 
and chitinase 3-like 1 (CHI3L1) to complement local cytokine 
profiles, rather than classical acute phase protein, such as serum 
amyloid A and haptoglobin. Both LCN2 and CHI3L1 are increas-
ingly reported as key players in a wide range of inflammatory 
diseases. LCN2 binds and sequesters the iron-scavenging sidero-
phore enterobactin, preventing Gram-negative bacterial iron 
acquisition (35, 36). Recently, it has been shown that secreted 
human LCN2 cloned into bovine mammary epithelial stem cells 
actively inhibits growth of mastitis-causing S. aureus as well (37). 
CHI3L1, on the other hand, belongs to the family of chitinase-like 
proteins and was initially reported in host antifungal responses 
as an important scavenger of chitin that is present in the fungal 
cell wall (38). However, further research demonstrated that the 
enzymatically inactive CHI3L1 has prominent functions in bac-
terial adhesion and invasion in host tissue, bacterial clearance, 
and innate immunity processes (39–43).
MaTerials anD MeThODs
intramammary inoculation Model
Hsd:ICR (CD1) outbred mice were purchased from a com-
mercial supplier (ENVIGO, The Netherlands). The mice were 
FigUre 1 | Experimental design. Hsd:ICR (CD1) 8-week-old female outbred mice were mated with 10-week-old male mice. The female mice were isolated for 
1 week to give birth to their offspring. To ease the intraductal accessibility of the lactating mothers, the 10-day-old pups were weaned 2 h before the first inoculation. 
Depending on the preconditioning experiment: lipopolysaccharide (LPS)/lipoteichoic acid (LTA)/PBS or ex vivo LPS-/LTA-/PBS-treated macrophages were injected 
24 h prior to the induction of Staphylococcus aureus mastitis in mice. To deplete local alveolar macrophages, preconditioning experiments could be preceded by 
clodronate liposome treatment. All intraductal injections (100 µl) were performed in the fourth gland pair of each of the mice. At relevant time points, post-inoculation 
mice were sedated and subsequently euthanized through cervical dislocation. Mammary glands were harvested to determine local bacterial loads, cytokine levels,  
or histopathology.
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fed ad libitum in a controlled environment that included light 
and dark cycles (12  h light: 12  h darkness). All the protocols 
that involved animals were approved by the Committee on 
the Ethics of Animal Experiments of the Faculty of Veterinary 
Medicine, Ghent University (permit number 2014/107 and 
2015/127). The experimental design of this study is shown 
in Figure  1. Eight-week-old female mice were mated with 
10-week-old male mice. To ease the intraductal accessibility 
of the lactating mothers, the 10-day-old pups were weaned 
2  h before the first inoculation. If possible the pups were 
transferred to foster mothers, the remaining pups were culled 
by CO2 in a closed compartment as approved by the ethical 
committee of the faculty. All intraductal injections (100  µl) 
using a 32-gauge blunt needle were performed in the fourth 
gland pair of each of the mice under isoflurane anesthesia com-
bined with the long-acting analgesic buprenorphine (10  µg/kg 
Vetergesic, Patheon UK Ltd., UK) and core body temperature 
was post-operative monitored with a rectal thermistor. Next to 
the ones described below, different agents were injected in the 
mammary gland, such as clodronate and PBS liposomes (Van 
Rooijen, The Netherlands). Inoculation of mammary glands 
with clodronate-containing liposomes depletes local alveolar 
macrophages and indirectly also decreases the recruitment of 
PMNs following intramammary LPS inoculation (27). At rele-
vant time points post-inoculation (p.i.) mice were sedated by an 
intraperitoneal administered mixture of ketamine (100 mg/kg 
Anesketin, Eurovet Animal Health BV, Bladel, The Netherlands) 
and xylazine (10 mg/kg; Xylazini Hydrochloridum, Val d’Hony-
Verdifarm, Belgium) and, subsequently, euthanized through 
cervical dislocation. Mammary glands were harvested to deter-
mine local bacterial loads, cytokine levels, or histopathology.
Bacterial Products
The mastitis isolate S. aureus Newbould 305 (ATCC 29740) was 
grown in brain heart infusion (Thermo Scientific, Belgium) broth 
for 5 h from a frozen stock. The CFU/mL was determined after 24 h 
of incubation at 37°C from the 1/100 diluted bacterial preculture 
by spectrophotometric measurements at 600  nm (OD600) and 
were confirmed a posteriori by plating on tryptic soy agar (Thermo 
Scientific, Belgium) plates. The pathogen was suspended in PBS 
to achieve the required concentration (103–104 CFU/100μl). This 
100 µl solution was then used to inoculate the mammary gland 
in the different mouse experiments (Figure  1). Ultrapure LPS 
0111:B4 (InvivoGen, USA) and ultrapure LTA from S. aureus 
(InvivoGen, USA) were suspended in endotoxin-free water and 
diluted to the required concentration in PBS. These 100 µl LPS 
and LTA solutions were injected 24 h prior to the intramammary 
infection with S. aureus (Figure 1).
cell culture
Peritoneal macrophages were isolated as described in Walachowski 
et al. (44) and plated out in DMEM/F12 (Gibco) with 10% fetal 
calf serum for 2 h according to Mosser and Edwards (45). The 
non-attached cells are washed out and the sticky macrophages 
were trypsinized, washed, and checked for their F4/80 (clone 
CI:A3-1AbD Serotec) positivity on a flow cytometer (Cytoflex, 
Beckman Coulter). Subsequently, macrophages were activated by 
exposing them in vitro to 10,000 EU LPS [referred to as M(LPS)], 
10,000 EU LTA [referred to as M(LTA)], or PBS [referred to as 
M(PBS)] for 24 h (45). Cells were then washed twice with PBS. As 
shown in the experimental design flow (Figure 1), these treated 
macrophages were injected in the mammary gland 24 h prior to 
a mammary infection with S. aureus.
Quantitative cytokine array, lcn2,  
and chi3l1 elisa
Hundred microliters of mammary gland homogenate were mixed 
with 300  µl lysis buffer supplemented with protease inhibitors 
(200  mM NaCl, 10  mM Tris–HCl pH 7.4, 5  mM EDTA, 1% 
Nonidet P-40, 10% glycerol, 1  mM oxidized l-glutathione, 
100  µM PMSF, 2.1  µM leupeptin, and 0.15  µM aprotinin) to 
extract cellular proteins. The suspensions rested overnight at 
−20°C, were centrifuged at 12,250 ×  g for 1  h, and finally the 
FigUre 2 | Effect of an intramammary injection with lipopolysaccharide (LPS) and lipoteichoic acid (LTA) on neutrophil recruitment in the intraductal mouse model. 
(a) Schematic presentation of the set-up. The white mammary glands represent the PBS (sham)-inoculated mammary glands, whereas the patterned glands 
represent the glands inoculated with LPS or LTA. (B) IL-8, a prototype chemoattractants for PMN influx was determined in mammary gland tissue 24 h p.i. of 
different doses of LPS and LTA (for inoculum dose 0.01, 0.1, 1, 10, and 10,000 EU LPS/LTA: n = 3 mice/6 glands; for inoculum dose 100 and 1,000 EU LPS/LTA: 
n = 2 mice/4 glands). Represented data were pooled from two independent experiments. Values are expressed as mean ± SEM. Significance between LPS-treated 
glands and PBS (sham)-inoculated mammary glands or significance between LTA-treated glands and PBS (sham)-inoculated mammary glands is illustrated without 
brackets. Values are expressed as mean ± SEM. **P < 0.01 and ***P < 0.001 versus sham. Significance between LPS- and LTA-inoculated glands is illustrated with 
brackets. Values are expressed as mean ± SEM. ***P < 0.001. (c) Mammary tissue was evaluated histologically p.i. with different doses of LPS or LTA. Immune 
cells in the alveolar lumen are indicated with black arrows and enlarged in the images below. Scale bar, 100 µm. p.i., post-inoculation.
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supernatant was centrifuged for another 30  min to obtain a 
clear pellet. Protein concentration of the lysate samples was 
determined as previously described (46). Cytokine quantifica-
tion (ProcartaPlex from eBioscience), LCN2 (Biotechne, USA), 
and CHI3L1 ELISA (Biotechne, USA) on the mammary gland 
lysates were all performed according to company guidelines or 
previously reported (47).
In Vivo imaging of activated PMn
When PMN are activated in inflamed tissues, myeloperoxidase 
(MPO) gets released and catalyzes the reaction of H2O2 and chlo-
ride ions (Cl−) to produce hypochlorous acid (HOCI) (48). In turn, 
HOCI can oxidize luminol (5-amino-2,3-dihydrophthalazine-
1,4-dione), which triggers chemiluminescence. MPO can also 
directly utilize superoxide anion as a substrate for peroxidase-
catalyzed oxidation of luminol (45). To visualize PMN activation 
in our model, we injected 10  mg/ml luminol (Sigma-Aldrich, 
USA) i.p. and detected the bioluminescent signal with the IVIS 
lumina II (Caliper) (49).
histopathology
Two mammary glands per condition were fixed in buffered 
3.5% formaldehyde for 24  h at room temperature, dehydrated, 
and embedded in paraffin wax. Sections were deparaffinized, 
hydrated, and stained with hematoxylin and eosin. Subsequently, 
sections were dehydrated and mounted with a cover glass.
statistical analysis
Statistical differences were determined on normalized data with 
an independent sample T-test (SPSS 20.0, IBM Corporation, 
USA). The statistical differences for multiple comparisons were 
determined using ANOVA tests. Statistical significance between 
different groups was determined through Tukey post hoc testing.
resUlTs
Both lPs, and to a lesser extent also  
lTa, induce Mammary immune cell 
recruitment and local il-8 induction
The effect of intramammary challenge with different doses (0.01–
10,000 EU) of either LPS or LTA was compared in mice at 24 h 
p.i. (Figure 2A). Mammary glands subjected to LPS at 10,000 EU 
had significantly higher IL-8 levels than glands exposed to a same 
dose of LTA 24 h p.i. (Figure 2B). While significant differences 
were detected in local IL-8 levels after a low-dose challenge of LPS 
(10 EU) compared to PBS (sham)-inoculated glands, IL-8 levels 
only increased in LTA challenged glands starting at a 100-fold 
higher dose (1,000  EU). This observation was in line with the 
histological data, showing the recruitment of immune cells in 
the alveolar lumen at a later time point for the mammary glands 
exposed to LTA compared to the mammary glands injected with 
LPS (Figure 2C).
FigUre 3 | Effect of an intramammary injection with lipopolysaccharide (LPS) and lipoteichoic acid (LTA) on local lipocalin 2 (LCN2) and chitinase 3-like 1 (CHI3L1) 
levels in the intraductal mouse model. LCN2 and CHI3L1 levels were determined in mammary gland tissue 24 h p.i. of different doses of LPS and LTA (n = 3 mice/6 
glands for inoculum dose 0.01, 0.1, 1, 10, and 10,000 EU LPS/LTA; n = 2 mice/4 glands for inoculum dose 100 and 1,000 EU LPS/LTA). Represented data were 
pooled from two independent experiments. p.i., post-inoculation. Values are expressed as mean ± SEM (**P < 0.01 and ***P < 0.001 versus sham).
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lPs Treatment More effectively induces 
local lcn2 and chi3l1 than lTa 
Treatment, Partially concomitant with 
Mammary immune cell recruitment
Lipopolysaccharide was more effective than LTA to significantly 
induce both mammary LCN2 and CHI3L1 compared to PBS 
(sham)-inoculated mammary glands (Figure  3). Nevertheless, 
it was also observed that local LCN2 and CHI3L1 levels not 
fully mimicked the previously mentioned IL-8 levels. Indeed, 
dissimilar to the IL-8 patterns, 10-fold higher doses of both LPS 
(≥100  EU) and LTA (10,000  EU) were needed to significantly 
induce CHI3L1 in the mammary gland compared to sham-
inoculated glands. Furthermore, no significant difference in 
LCN2 and CHI3L1 levels could be observed between the LPS and 
LTA inductions at the highest dose (10,000  EU). Interestingly, 
recruitment of neutrophils was observed in the mammary alveoli 
at the time point that both the LCN2 and CHI3L1 levels in the 
LTA and LPS groups were significantly increased compared to the 
PBS (sham)-inoculated glands.
S. aureus effectively recruits immune 
cells during Mammary-induced 
inflammation independently of lcn2
In contrast to sterile mammary gland-induced inflammation, 
inoculation of 1,000 CFU S. aureus Newbould 305 (S. aureus) 
in the murine mammary gland resulted in high bacterial counts 
(9.2 ±  0.3 log10  CFU/g mammary gland), accompanied by a 
prominent local host response at 24  h p.i. (Figure  4A). This 
inflammatory response was characterized by the production of 
multiple cytokines and chemokines as comparing tissue samples 
of a S. aureus- and a PBS (sham)-inoculated murine mammary 
gland (data not shown). In addition, the significant increase of 
IL-8 levels at 24 p.i. in the S. aureus-infected glands compared 
to sham-inoculated control glands could be demonstrated 
(Figure  4B, left). This latter observation could be confirmed 
upon histological examination through a pronounced presence 
of immune cells in the lumen of the mammary alveoli with 
S. aureus, compared to sham-inoculated mammary glands 
(Figure 4B, right). Interestingly, the IL-8 levels showed a median 
fold increase of 14.0 between S. aureus- and sham-inoculated 
mammary glands, whereas a 34.1 and 14.6 median fold increase 
was observed for 10,000  EU LPS- or LTA-exposed mammary 
glands, respectively, compared to the control glands. Although 
LCN2 levels in these infected glands were not significantly dif-
ferent from the LCN2 levels in sham-inoculated control glands, 
local induction of CHI3L1 levels by S. aureus could still be 
observed at 24 h p.i. (Figure 4C). More specifically, the median 
fold increase of local CHI3L1 levels in S. aureus-inoculated 
glands compared to sham-inoculated control glands was 2.88, 
which is an order of magnitude lower compared to the CHI3L1 
levels following exposure to 10,000 EU LPS or LTA (8.16 and 
5.13, respectively).
Preconditioning of the complete 
Mammary gland compartment with lPs 
or lTa strongly immunomodulates S. 
aureus Mastitis, reducing Bacterial 
loads, recruiting PMn, and increasing 
local chi3l1 or lcn2 levels, 
respectively
As shown in Figure  1, mice were intramammary injected 
with PBS, LPS (10,000 EU), or LTA (10,000 EU) 24 h prior to 
S. aureus infection. With this setup, we wanted to verify whether 
LPS or LTA preconditioning is able to boost the murine 
mammary gland microenvironment against a S. aureus infec-
tion (Figure 5A). All mice pretreated with either LPS or LTA 
showed a significant decrease in local bacterial loads 24 h p.i. 
with S. aureus compared to PBS (sham)-pretreated mammary 
glands (Figure 5B). Histology also showed that all conditions 
were characterized by the presence of PMN in the alveoli of the 
mammary glands at 24 p.i. with S. aureus (Figure 5C). However, 
on the molecular level, this observation during LPS and LTA 
pretreatment was accompanied with a significant reduction 
in mammary IL-8 levels compared to sham preconditioning 
(Figure 5D).
As previously shown, preconditioning with PBS prior to 
S. aureus infection induced low levels of CHI3L1, but did not 
induce LCN2 levels in the mammary gland. Preconditioning with 
FigUre 4 | Inflammatory response to an intramammary infection with Staphylococcus aureus in mice. (a) Schematic presentation of the experimental set-up.  
The white mammary glands represent the PBS (sham)-inoculated mammary glands, whereas the black glands represent the glands inoculated with S. aureus.  
(B) Quantitative levels of IL-8 determined in mammary gland tissue to PBS (sham) and S. aureus 24 h p.i. (left) (PBS inoculation: n = 10 glands; S. aureus 
inoculation: n = 8 glands). Representative images of alveoli of mammary glands exposed to PBS (sham) (bottom) and S. aureus (top) 24 h p.i. (right). Scale bar, 
20 µm. (c) Lipocalin 2 and chitinase 3-like 1 levels were determined in mammary gland tissue 24 h after intramammary exposure with PBS or S. aureus (PBS 
inoculation: n = 6 glands; S. aureus inoculation: n = 7 glands). Represented data were pooled from three independent experiments. p.i., post-inoculation. Values are 
expressed as mean ± SEM (***P < 0.001).
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10,000 EU LPS or LTA prior to S. aureus infection, on the other 
hand, boosted either one of these innate immune biomarkers 
(Figure 5E). More specifically, a significant increase in mammary 
CHI3L1 levels was detected with LPS preconditioning prior to 
S. aureus infection, whereas a significant increase in mammary 
LCN2 levels was observed with LTA preconditioning prior to 
S. aureus infection.
Local cytokine profiling showed that the inflammatory response 
following infection with S. aureus was influenced by the LPS and 
LTA preconditioning at an inoculum dose of 10,000  EU. IL-1 
alpha, IL-1 beta, IL-17A, IL-6, MCP-1, and TNF-alpha followed 
the same pattern as the neutrophil chemoattractant IL-8 profile 
and were significantly reduced by LPS and LTA precondition-
ing compared to PBS preconditioning in the S. aureus-infected 
mammary glands (Figure 5F). Mammary RANTES/CCL5 levels 
were significantly increased by LPS preconditioning compared 
to the other conditions, while LTA preconditioning significantly 
reduced local BAFF levels compared to PBS preconditioning 
(Figure 5G).
alveolar Macrophages have an 
immunomodulatory Function during  
lPs and lTa Preconditioning against  
S. aureus-induced Mastitis
Alveolar macrophages are a major innate immune cell type in 
the mammary gland that contain PRRs on the cell surface to 
sense bacterial antigens (such as LPS or LTA). Macrophages are 
known to be a crucial cell type during immune tolerance, e.g., 
endotoxin tolerance. It is a protective mechanism against exces-
sive inflammation where macrophages change their responsive-
ness to LPS following a first exposure to LPS (50). To test their 
immunomodulatory potential of macrophages in the mammary 
gland, isolated murine peritoneal macrophages were exposed ex 
vivo either to 10,000 EU LPS [referred to as M(LPS)], 10,000 EU 
LTA [referred to as M(LTA)] or PBS [referred to as M(PBS)]. The 
response of these macrophages was subsequently verified with 
the two previously used innate immune biomarkers LCN2 and 
CHI3L1. Activated macrophages, i.e., M(LPS) as well as M(LTA), 
FigUre 5 | Continued
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FigUre 5 | The effect of lipopolysaccharide (LPS) or lipoteichoic acid (LTA) preconditioning on Staphylococcus aureus mastitis in mice. (a) Schematic presentation 
of the experimental set-up. Following PBS (white), LPS (checkered pattern) or LTA (striped pattern) preconditioning, mammary glands were inoculated with S. aureus 
(black). (B) Bacterial loads in mammary glands that received PBS, LPS, or LTA preconditioning prior to a S. aureus infection (PBS + S. aureus: n = 6 glands; 
LPS + S. aureus: n = 7 glands; LTA + S. aureus: n = 8 glands). (c) Representative images of alveoli of mammary glands that had PBS, LPS, or LTA preconditioning 
prior to a S. aureus infection. PMN are indicated by an arrow. Scale bar, 100 µm. (D) The IL-8 levels in mammary glands that received PBS, LPS, or LTA 
preconditioning prior to a S. aureus infection (PBS + S. aureus: n = 14 glands; LPS + S. aureus: n = 17 glands; LTA + S. aureus: n = 8 glands). (e) Lipocalin 2 
(LCN2) and chitinase 3-like 1 (CHI3L1) levels in mammary glands that received PBS, LPS, or LTA preconditioning prior to a S. aureus infection (LCN2: n = 14 glands 
for PBS + S. aureus, n = 17 glands for LPS + S. aureus, n = 8 glands for LTA + S. aureus; CHI3L1: n = 8 glands for PBS + S. aureus, n = 16 glands for  
LPS + S. aureus, n = 17 glands for LTA + S. aureus). (F) IL-1 alpha, IL-1 beta, MCP-1 IL-17A, TNF-alpha, and IL-6 levels in mammary glands that received 
clodronate before LPS or LTA preconditioning prior to a S. aureus infection (PBS + S. aureus: n = 14 glands; LPS + S. aureus: n = 17 glands; LTA + S. aureus: 
n = 8 glands). (g) RANTES/CCL5, and BAFF levels in mammary glands that received clodronate before LPS or LTA preconditioning prior to a S. aureus infection 
(PBS + S. aureus: n = 14 glands; LPS + S. aureus: n = 17 glands; LTA + S. aureus: n = 8 glands). Represented data were pooled from three independent 
experiments. p.i., post-inoculation. Values are expressed as mean ± SEM (*P < 0.05, **P < 0.01, and ***P < 0.001).
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were found to secrete significantly more LCN2 and CHI3L1 
than non-activated macrophages, i.e., M(PBS) (Figure 6A). Of 
notice, the secreted levels of both these innate immune biomarker 
proteins showed a significantly higher increase with M(LPS) than 
with M(LTA).
In a next step, the immune modulating effect of these 
M(LPS)- versus M(LTA)-activated macrophages was studied in 
a mammary gland environment. As shown in Figure 1, M(PBS), 
M(LPS), or M(LTA) were first transferred into murine mam-
mary glands, followed by an inoculation with 104 CFU S. aureus 
bacteria or a PBS (sham) inoculation 24 h later (Figure 6B). The 
transfer of M(PBS), M(LPS), or M(LTA) did not significantly 
decrease the bacterial loads in the murine mammary glands at 
24 p.i. with S. aureus. Nevertheless, there were 40 and 43% of the 
mammary glands in, respectively, the M(LPS) and the M(LTA) 
transfer group that had a decreased bacterial load p.i. with 
S. aureus (Figure 6C). In comparison, the number of glands with 
a decrease in bacterial loads in the M(PBS)-transferred glands 
was 17%.
The non-significant difference in bacterial loads between 
the different transfer groups p.i. with S. aureus can be reasoned 
by the lack of PMN recruitment induced by the activated 
macrophages. Indeed, based on histology, M(PBS), M(LPS), or 
M(LTA) transfer followed by sham inoculation 24 h later did not 
induce any recruitment of PMN at 48 h post-macrophage transfer 
(Figure 6D). The absence of PMN in the alveolar lumen could 
also be observed based on the low mammary IL-8 levels in the 
glands that received M(PBS), M(LPS), or M(LTA) followed by 
sham inoculation (Figure  6E, left). By contrast, the mammary 
glands that were infected with S. aureus at 24 h post-macrophage 
transfer displayed a significantly increased IL-8 response com-
pared to M(PBS) and PBS (sham). Moreover, statistical analysis 
showed that the M(PBS), M(LPS), and M(LTA) transfer induced 
a different IL-8 response in the infected mammary glands. To 
visualize these differences in IL-8 levels more easily, the effect 
of macrophage transfer followed by S. aureus inoculation in the 
murine mammary gland was standardized with the IL-8 levels 
measured following macrophage transfer and subsequent sham 
inoculation (Figure 6E, right). This analysis showed that immune 
tolerance was limited with M(LPS) while the transfer of M(LTA) 
followed by S. aureus infection significantly decreased the IL-8 
response in the challenged murine mammary glands compared to 
M(PBS) and M(LPS) transfer and subsequent S. aureus infection.
Next, we investigated whether LPS- and LTA-activated 
macrophages modulate the response of both LCN2 and CHI3L1 
in  vivo to a similar extent as in  vitro. Standardizing the LCN2 
and CHI3L1 levels with M(LPS), M(LTA), and M(PBS) transfer 
in infected versus non-infected mammary glands showed that 
M(LPS) transfer significantly boosted both local LCN2 and 
CHI3L1 levels compared to M(PBS) or M(LTA) transfer upon 
S. aureus infection (Figure 6F). By contrast, but similarly to what 
was found in vitro, M(LTA) induced lower local LCN2 levels fol-
lowing S. aureus inoculation, compared to the M(LPS) transfer 
group. Local CHI3L1 levels, however, were not induced by the 
M(LTA) transfer group upon S. aureus infection (Figure 6F).
Local cytokine profiling further identified a partly and differ-
ential immunosuppressive effect due to the activated macrophages 
(Figure  6G). A significant decrease in the levels of MCP-1, 
IL-17A, and IL-1 alpha was observed after M(LTA) transfer in 
the mammary glands p.i. with S. aureus compared to M(PBS) 
transfer. M(LPS) transfer only induced a significant decrease in 
IL-17A levels compared to M(PBS) transfer. Other cytokines that 
showed elevated levels at 24 h p.i. with S. aureus included IL-6, 
IL-1 beta, RANTES/CCL5, and BAFF remained unaltered with 
M(LPS) and M(LTA) transfer compared to M(PBS) transfer (data 
not shown).
FigUre 6 | Continued
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FigUre 6 | The effect of ex vivo activated macrophages on an intramammary infection with Staphylococcus aureus in mice. (a) Lipocalin 2 (LCN2) and chitinase 
3-like 1 (CHI3L1) levels were determined in medium of harvested peritoneal macrophages 24 h post-exposure to PBS [M(PBS)], lipopolysaccharide (LPS) [M(LPS)], 
or lipoteichoic acid (LTA) [M(LTA)] (n = 3 for each group). Represented data were collected from one experiment. (B) Schematic presentation of the set-up. 
Macrophages ex vivo exposed to PBS (white glands), LPS or LTA (patterned glands) were transferred into mammary glands and inoculated with PBS (sham) or 
infected with S. aureus. (c) Bacterial loads 24 h p.i. with S. aureus in mammary glands that received M(PBS), M(LPS), or M(LTA) transfer [M(PBS): n = 12 glands; 
M(LPS): n = 14 glands; M(LTA): n = 10 glands]. (D) Representative images of alveoli of mammary glands that received M(PBS), M(LPS), or M(LTA) transfer followed 
by PBS (sham). Transferred macrophages are indicated by an arrow. Scale bar, 100 µm. (e) Quantitative levels of IL-8 determined in mammary gland tissue that 
received M(PBS), M(LPS), or M(LTA) transfer followed by an inoculation with PBS (sham) or S. aureus (left) [PBS inoculations: n = 12 glands for M(PBS), n = 13 
glands for M(LPS), n = 12 glands for M(LTA); S. aureus inoculations: n = 12 glands for M(PBS), n = 6 glands for M(LPS), n = 4 glands for M(LTA)]. Normalized 
quantitative IL-8 values between macrophage transferred glands that received PBS (sham) or S. aureus. (F) Normalized quantitative LCN2 and CHI3L1 levels 
between M(PBS), M(LPS), or M(LTA) transferred glands that received PBS (sham) or S. aureus [LCN2: n = 11 glands for M(PBS), n = 14 glands for M(LPS), n = 10 
glands for M(LTA); CHI3L1: n = 12 glands for M(PBS), n = 12 glands for M(LPS), n = 12 glands for M(LTA)]. (g) Normalized quantitative MCP-1, IL-17A, and IL-1 
alpha levels between M(PBS), M(LPS), or M(LTA) transferred glands that received PBS (sham) or S. aureus [M(PBS): n = 17 glands; M(LPS): n = 19 glands; M(LTA): 
n = 16 glands]. Represented data were pooled from three independent experiments. p.i., post-inoculation. Values are expressed as mean ± SEM (*P < 0.05, 
**P < 0.01, and ***P < 0.001).
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Macrophage-independent signaling is 
important for Bacterial clearance and 
immunomodulation during Mammary 
gland Preconditioning with lPs and lTa 
against S. aureus-induced Mastitis
Clodronate liposomes were used to verify the influence of 
macrophage depletion p.i. LPS or LTA (Figure 7A). Histology 
showed that intramammary inoculation of clodronate-containing 
liposomes could decrease the recruitment of PMN in the alveoli 
of the mammary gland upon challenge with LPS, whereas inocu-
lation of PBS-containing liposomes followed by LPS challenge 
resulted in a typical strong influx of PMN (Figure  7B). This 
distinction was not clearly observed when comparing both 
liposome groups upon challenge with LTA. Luminol-dependent 
bioluminescence is able to visualize detection of MPO activ-
ity and its use in  vivo is specified for active PMN rather than 
macrophages. In vivo imaging with luminol confirmed the 
effect of clodronate treatment in the murine mammary gland 
upon LPS challenge by a decreased MPO activity compared to 
the mammary glands that were treated with PBS-containing 
liposomes (Figure 7C). Of note, the low recruitment or activity 
of PMN by LTA compared to LPS as seen previously, impaired 
the visualization of the bioluminescent signal from luminol in 
both conditions. These observations indicate that clodronate 
treatment has mainly an effect on LPS- rather than LTA-induced 
inflammation. This was also indirectly shown through the 
stronger decrease in mammary IL-8 levels following clodronate 
treatment in the LPS-challenged group compared to the LTA-
challenged group (Figure 7D).
To verify whether other PRR-expressing mammary cells—next 
to macrophages—may be activated and have immunomodula-
tory effects during a S. aureus infection, mammary glands of 
mice were challenged with a clodronate- or PBS-containing lipo-
some treatment followed by either LPS or LTA challenge (both 
10,000 EU) and a S. aureus infection (Figures 1 and 8A). Local 
depletion of macrophages by clodronate-containing liposomes 
did not significantly increase the local bacterial loads when 
LPS or LTA was intramammarily inoculated prior to S. aureus 
(Figure  8B). However, the innate immune response following 
FigUre 7 | Effect of clodronate liposome treatment on lipopolysaccharide (LPS)- and lipoteichoic acid (LTA)-induced PMN recruitment in the murine mammary 
gland. (a) Schematic presentation of the experimental set-up. The white mammary glands represent the PBS liposome inoculated mammary glands, whereas the 
gray color gradient glands represent the glands that received clodronate. Following this liposome treatment, mammary glands were inoculated once more with either 
LPS (checkered pattern) or LTA (striped pattern). (B) Representative images of alveoli of mammary glands that received clodronate followed by LPS or LTA. PMN are 
indicated by an arrow. Scale bar, 100 µm. (c) Luminol-based bioluminescence imaging of mouse mammary glands that received clodronate followed by LPS or LTA 
(n = 3 mice for each group). (D). Normalized quantitative IL-8 values between PBS and clodronate inoculation in the mammary glands to compare the differences 
between LPS or LTA treatment (n = 6 glands for each group). Represented data were pooled from three independent experiments. p.i., post-inoculation.
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S. aureus infection was influenced by this depletion as IL-8 levels 
significantly increased in infected mammary glands challenged 
with either LPS or LTA (Figure 8C).
In this experimental setup, LCN2 and CHI3L1 also showed 
different patterns upon S. aureus infection in the LPS- versus 
LTA-challenged groups. Intramammary inoculation with 
clodronate-containing liposomes and subsequent LTA, but not 
LPS preconditioning significantly increased local LCN2 levels 
compared to the PBS liposome treatment in infected glands. By 
contrast, local CHI3L1 levels were decreased in mammary glands 
FigUre 8 | Continued
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that received LPS preconditioning and clodronate treatment fol-
lowed by S. aureus infection. Liposomes in the mammary gland 
did not affect the local CHI3L1 levels p.i. with LTA precondition-
ing followed by S. aureus infection (Figure 8D).
Local cytokine profiling also showed that, similar to the neu-
trophil attractant IL-8 profile, the macrophage chemoattractant 
MCP-1 as well as IL-6 were increased by the macrophage deple-
tion process both with LPS and LTA preconditioning followed by 
FigUre 8 | Continued  
Effect of clodronate liposome treatment on lipopolysaccharide (LPS) and lipoteichoic acid (LTA)—preconditioning to Staphylococcus aureus in the murine mammary 
gland. (a) Schematic presentation of the experimental set-up. The treatment groups of Figure 7 received an infection with S. aureus (black glands) 24 h p.i. (B) The 
bacterial loads in mammary glands that received clodronate before LPS or LTA preconditioning prior to a S. aureus infection (n = 7) glands for the PBS liposome 
groups (i.e., macrophage +); n = 10 glands for the clodronate liposome groups (i.e., macrophage −). (c) The IL-8 levels in mammary glands that received 
clodronate injection before LPS or LTA preconditioning prior to a S. aureus infection (PBS liposomes: n = 8 for the LPS preconditioning group, n = 6 for the LTA 
preconditioning group; clodronate liposomes: n = 10 for both the LPS and LTA preconditioning group). (D) Lipocalin 2 (LCN2) and chitinase 3-like 1 (CHI3L1) levels 
in mammary glands that received clodronate injection before LPS or LTA preconditioning prior to a S. aureus infection [PBS liposomes: n = 7 (LCN2/CHI3L1) for the 
LPS preconditioning group, n = 7 (LCN2) and n = 8 (CHI3L1) for the LTA preconditioning group; clodronate liposomes: n = 8 (LCN2) and n = 10 (CHI3L1) for both 
the LPS preconditioning group, n = 10 (LCN2/CHI3L1) for the LTA preconditioning group]. (e) MCP-1, IL-17A, RANTES/CCL5, BAFF, and IL-6 levels in mammary 
glands that received clodronate injection before LPS or LTA preconditioning prior to a S. aureus infection (n = 7 glands for the PBS liposome groups; n = 10 glands 
for the clodronate liposome groups). Represented data were collected from one experiment. Values are expressed as mean ± SEM. ns, not statistically significant; 
p.i., post-inoculation (*P < 0.05, **P < 0.01, and ***P < 0.001).
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S. aureus infection (Figure 8E). BAFF was only affected by clo-
dronate treatment in the LPS-pretreated group with S. aureus infec-
tion. IL-17A and RANTES levels, respectively, were significantly 
increased and decreased, respectively, in the LTA-pretreated group 
with clodronate-depleted macrophages and S. aureus infection.
DiscUssiOn
Staphylococcus aureus mastitis is contagious and does not 
respond well to classical antibiotic therapies (12–14). This 
Gram-positive pathogen is characterized by biofilm forma-
tion and intra-epithelial localization, which hinder access of 
therapeutic agents (11). Consequently, S. aureus udder infec-
tions have led to the overuse of antibiotics that increases drug 
resistance (51–53). Therefore, either novel vaccination or other 
innovative preventive measures with negligible side-effects are 
highly anticipated as they have remained unsuccessful in Gram-
positive mastitis (7).
The hosts’ recognition of pathogen-associated factors and 
its innate immune response determines the outcome of bovine 
mastitis (54, 55). The persistent character of S. aureus udder 
infections is believed to result from a limited mammary cytokine 
production compared to the “cytokine storm” raised against E. coli 
(20, 21). This implies that E. coli antigens are either more easily 
recognized by mammary PRR or that Gram-negative virulence 
factors have a higher potency to trigger a strong local immune 
response. In this study, the dose-dependent stimulation with LPS 
versus LTA allowed controlled investigation of the potency and 
differential activation of PRRs through monitoring of local IL-8 
production and immune cell infiltration at 24  h p.i. Histology 
demonstrated that the highest inoculum dose of LPS and LTA 
initiated innate immune cell recruitment. However, the innate 
immune response was significantly faster and higher stimulated 
by LPS compared to LTA.
It has been suggested that LPS may influence the course of a 
subsequent bacterial udder infection (56, 57). More specifically, 
injection of LPS in the udder reduced the severity of a subsequent 
experimental E. coli mastitis (57). Whether preconditioning 
enhances the pathogen recognition or the host immune response is 
not clear. Staphylococcus aureus stimulates TLR2 but lacks efficient 
activation of TLR4 compared to E. coli (58, 59). Similarly, as TLR4 
activation by LPS is protective against E. coli mastitis, this study 
aimed to boost TLR2-induced immune response of the murine 
mammary microenvironment by LTA to protect the host against 
S. aureus mastitis. On the other hand, we also explored the pos-
sibility that we should compensate for the lack of TLR4 signaling 
during S. aureus mastitis by preconditioning with LPS. Our results 
confirmed the observations previously suggested for an in vitro S. 
aureus infection (60, 61): preconditioning the host significantly 
reduced bacterial loads at 24 h p.i. We also described the participa-
tion of local chemo- or cytokines. Although several major local 
pro-inflammatory mediators decreased, the host was still able to 
recruit neutrophils to the lumen of LPS or LTA preconditioned 
alveoli. The lower local IL-8 levels are, therefore, likely an indica-
tion of abolished further neutrophil recruitment rather than of 
their initial LPS- or LTA-induced recruitment. In addition, local 
MCP-1 and IL-17A levels are signature cytokines for macrophage 
recruitment and T helper cell activation, indicating that the immu-
nomodulatory response is not limited to neutrophils. On the one 
hand, LTA but not LPS preconditioning additionally lowered local 
BAFF levels, a cytokine necessary for proliferation and differentia-
tion of B cells. On the other hand, LPS but not LTA preconditioning 
elevated local RANTES/CCL5 levels, in line with the in vitro obser-
vations of cytokine networks after recurrent exposure of bovine 
MECs to LPS (56). Overall, our different preconditioning protocols 
against S. aureus mastitis together with the reported sterile mam-
mary inflammation data indicate that the two key Gram-negative 
and -positive virulence factors have unique traits and differentially 
immunomodulate the mouse mammary gland.
Mammary sentinel cell types—each featuring a distinct 
immune competence—govern the host response to virulence 
factors in the mammary gland (16). Some mammary epithelial 
tissue exposure experiments have described an effect of LPS and 
LTA on the innate immune response, but how these key virulence 
factors modulate the mammary gland microenvironment has 
been scarcely studied in vitro and especially in vivo (16, 27, 32). 
The validated murine intramammary inoculation model previ-
ously demonstrated that local macrophages are of key importance 
for the LPS–TLR4 axis-mediated neutrophil recruitment into the 
alveolar lumen, while this is far less the case for TLR2-mediated 
signaling (27, 62). In general, macrophages can be programmed 
to different priming and tolerance states by varying dosages of 
LPS (63). Partly corroborating the observations from our in vivo 
sterile mammary inflammation data, we demonstrated that 
macrophages alone affect the mammary environment albeit to a 
limited degree. Indeed, in vitro preconditioning of alveolar mac-
rophages with either LPS or LTA, and their transfer into sterile 
murine mammary glands did not induce a neutrophil influx. 
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Moreover, upon S. aureus infection, activation of these differently 
preconditioned macrophages reduced the bacterial loads only 
to a limited extend compared to sham-exposed macrophages. 
Of relevance, the different TLR trigger changed the response of 
macrophages as LTA-dependent macrophage signaling was more 
efficient in reducing the inflammatory signaling compared to the 
LPS-dependent macrophage signaling.
Injection of macrophages treated with LPS or LTA into 
the gland prior to infection attenuates the S. aureus-induced 
cytokine release when compared to mice receiving PBS-treated 
macrophages. However, the pretreated transferred macrophages 
are not sufficient to reduce the bacterial burden, suggesting that 
LPS and LTA have to act directly on cells in the mammary gland. 
MECs have been proposed as special non-professional sentinel 
cells that are responsible for macrophage-independent local 
signaling (64). To investigate the role of the mammary epithelium 
in the LPS- and LTA-mediated immunomodulatory response 
against S. aureus, macrophages were depleted in our precondi-
tioning mastitis model by clodronate-containing liposomes. This 
local treatment did not change the antibacterial host response, 
but strongly immunomodulated a subsequent mammary 
S. aureus infection. Consequently, the antibacterial response after 
preconditioning with either LPS or LTA likely originated from 
macrophage-independent signaling by the mammary epithelium. 
Moreover, these data extend those obtained with the precondi-
tioned macrophages. Indeed, macrophages again immunomodu-
lated the mammary compartment during preconditioning 
as clodronate depletion influenced the local cytokine profile. 
Depletion of local macrophages was able to further distinguish the 
differential LPS versus LTA immunomodulatory signaling prior 
to a S. aureus infection. More specifically, our data showed that 
macrophages inhibited BAFF levels upon LPS preconditioning, 
while inhibiting IL-17A upon LTA preconditioning. In addition, 
macrophages had a pro-inflammatory effect by induction of 
RANTES/CCL5 upon LTA preconditioning prior to S. aureus 
infection. However, based on the methods used in this study, it is 
not possible to verify whether the changes in cytokine, chemokine, 
and antimicrobial peptide levels following clodronate pretreat-
ment and subsequent LPS/LTA preconditioning followed by a 
S. aureus infection are either due to an enhanced protein production 
by the mammary epithelia or the consequence of a reduced uptake 
by the macrophages after their depletion. Gene expression profiles 
on isolated mammary cell types would be of added value to distin-
guish between both phenomena, albeit these were not assessed in 
this study. In essence, mammary macrophages support the MECs 
to respond adequately to a local infection. This corroborates the 
key observations that alveolar macrophages aid the lung epithelia 
in tissue homeostasis (65) and local immune response (66).
Complementing the local cytokine profiles, we at first evalu-
ated LCN2 and CHI3L1 as potential in vivo and in vitro innate 
immunity modulators in the context of mastitis. Both LCN2 and 
CHI3L1 are stored in granules from mature human neutrophils 
(67–69). In line with our demonstration of neutrophils on his-
tology, increasing doses of LPS or LTA in the mammary gland 
comparably induced local LCN2 and CHI3L1 levels. However, no 
difference was seen at 24 h p.i. for either LPS or LTA at the highest 
inoculum dose (10,000 EU) as expected based on the differential 
local IL-8 patterns. Moreover, during S. aureus-induced mastitis, 
a salient finding was that neutrophil recruitment only caused a 
limited induction of local CHI3L1 and even no increase in mam-
mary LCN2 compared to sham inoculation. These unexpected 
data strongly indicated that S. aureus, in marked contrast to 
its key virulence factor LTA, did not fully trigger this innate 
immune signaling even if the basic mastitis characteristic, i.e., 
neutrophil influx was present. Moreover, our data indicated that 
neutrophils can be ruled out as the (only) source of LCN2 and 
CHI3L1, as a strong increase of both innate immune signals was 
absent in experimental S. aureus murine mastitis. Nonetheless, 
we showed a macrophage-dependent induction of both LCN2 
and CHI3L1 in the mammary compartment found to be typi-
cally triggered by LPS and less by LTA. Indeed, the latter virulence 
factor had a remarkably limited influence on the local cytokine 
profile. By contrast, clodronate treatment demonstrated that the 
macrophage-independent triggering by LPS was characterized by 
a strong induction of local CHI3L1 but not of LCN2. Again in 
marked contrast, LTA now also had a major influence, however, 
selectively on LCN2 and not on CHI3L1. These important findings 
strongly indicate that the LPS-induced upregulation of CHI3L1 in 
the mammary gland is mainly mediated by local macrophages, 
while the LTA-induced upregulation of LCN2 is inhibited by mac-
rophages. Based on the local cytokine patterns combined with 
the LCN2 and CHI3L1 levels, a complex interplay between mac-
rophages and the MECs occurs which is of critical importance to 
effectively induce antibacterial and anti-inflammatory processes 
and which encompasses either LCN2 or CHI3L1 induction.
In conclusion, extrapolation of our preclinical data allows 
us to suggest that during a bovine S. aureus-induced mastitis, 
the effective activation of host innate immunity in the murine 
mammary gland is lacking. We unequivocally demonstrated 
that activation of the complete mammary gland microenviron-
ment is required to effectively clear this Gram-positive infection 
and dampen the associated local pro-inflammatory cytokine 
response. Our current data also underscore the added value of 
the novel sentinel markers such as LCN2 and CHI3L1 that can 
be induced by different mammary cell types and may aid in the 
evaluation of preconditioning protocols.
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